-
公开(公告)号：US20060211689A1
公开(公告)日：2006-09-21
申请号：US11344440
申请日：2006-01-31
申请人： Peter Aranyi , Sandor Batori , Geza Timari , Kinga Boer , Zoltan Kapui , Endre Mikus , Katalin Urban-Szabo , Katalin Gerber , Judit Vargane Szeredi , Michel Finet
发明人： Peter Aranyi , Sandor Batori , Geza Timari , Kinga Boer , Zoltan Kapui , Endre Mikus , Katalin Urban-Szabo , Katalin Gerber , Judit Vargane Szeredi , Michel Finet
IPC分类号： A61K31/541 , A61K31/5377 , A61K31/496 , A61K31/4709 , C07D417/02 , C07D413/02 , C07D401/02
CPC分类号： C07D405/12 , C07C229/50 , C07D215/48 , C07D405/14 , C07D409/12 , C07D409/14 , C07D491/04
摘要： The present invention relates to an adenosine A3 receptor ligand of the general formula (I), within those preferably to the antagonists, including a salt, solvate or isomer (tautomer, desmotrop, and optically active isomer) thereof, to a pharmaceutical composition containing the ligand, to the use of the ligand, to its preparation, and intermediates of the ligand of the general formula (II″), (III″), (IV″), (V″), (VI″), (VII″), (VIII″) and (XIII″) and their preparation.
摘要翻译： 本发明涉及通式（I）的腺苷A 3 N 3受体配体，其中优选包括盐，溶剂合物或异构体（互变异构体，去质性和光学活性异构体） （II“），（III”），（IV“），（V）的配体的配体的使用，其制备方法和中间体的含有配体的药物组合物， （VI“），（VII”），（VIII“）和（XIII”）及其制备。
-
公开(公告)号：US08071601B2
公开(公告)日：2011-12-06
申请号：US13008398
申请日：2011-01-18
申请人： Peter Aranyi , Sandor Batori , Geza Timari , Kinga Boer , Zoltan Kapui , Endre Mikus , Katalin Urban-Szabo , Katalin Gerber , Judit Vargane Szeredi , Michel Finet
发明人： Peter Aranyi , Sandor Batori , Geza Timari , Kinga Boer , Zoltan Kapui , Endre Mikus , Katalin Urban-Szabo , Katalin Gerber , Judit Vargane Szeredi , Michel Finet
IPC分类号： A61K31/497 , A61K31/47 , C07D401/04 , C07D453/04
CPC分类号： C07D405/12 , C07C229/50 , C07D215/48 , C07D405/14 , C07D409/12 , C07D409/14 , C07D491/04
摘要： The present invention relates to an adenosine A3 receptor ligand of the general formula (I).
摘要翻译： 本发明涉及通式（I）的腺苷A3受体配体。
-
公开(公告)号：US07799922B2
公开(公告)日：2010-09-21
申请号：US12484658
申请日：2009-06-15
申请人： Peter Aranyi , Sandor Batori , Geza Timari , Kinga Boer , Zoltan Kapui , Endre Mikus , Katalin Urban-Szabo , Katalin Gerber , Judit Vargane Szeredi , Michel Finet
发明人： Peter Aranyi , Sandor Batori , Geza Timari , Kinga Boer , Zoltan Kapui , Endre Mikus , Katalin Urban-Szabo , Katalin Gerber , Judit Vargane Szeredi , Michel Finet
IPC分类号： C07D215/38 , C07D215/54 , C07D215/56
CPC分类号： C07D405/12 , C07C229/50 , C07D215/48 , C07D405/14 , C07D409/12 , C07D409/14 , C07D491/04
摘要： The present invention relates to an adenosine A3 receptor ligand of the general formula (I), within those preferably to the antagonists, including a salt, solvate or isomer (tautomer, desmotrop, and optically active isomer) thereof, to a pharmaceutical composition containing the ligand, to the use of the ligand, to its preparation, and intermediates of the ligand of the general formula (II″), (III″), (IV″), (V″), (VI″), (VII″), (VIII″) and (XIII″) and their preparation.
摘要翻译： 本发明涉及通式（I）的腺苷A3受体配体，其中优选包括其盐，溶剂化物或异构体（互变异构体，去质性和旋光异构体）的拮抗剂，包含其中的 通式（II“），（III”），（IV“），（V”），（VI“），（VII”）的配体的配体，配体的使用， ），（VIII“）和（XIII”）及其制备。
-
公开(公告)号：US07547696B2
公开(公告)日：2009-06-16
申请号：US11344440
申请日：2006-01-31
申请人： Peter Aranyi , Sandor Batori , Geza Timari , Kinga Boer , Zoltan Kapui , Endre Mikus , Katalin Urban-Szabo , Katalin Gerber , Judit Vargane Szeredi , Michel Finet
发明人： Peter Aranyi , Sandor Batori , Geza Timari , Kinga Boer , Zoltan Kapui , Endre Mikus , Katalin Urban-Szabo , Katalin Gerber , Judit Vargane Szeredi , Michel Finet
IPC分类号： A61K31/535 , C07D413/12
CPC分类号： C07D405/12 , C07C229/50 , C07D215/48 , C07D405/14 , C07D409/12 , C07D409/14 , C07D491/04
摘要： The present invention relates to an adenosine A3 receptor ligand of the general formula (I), within those preferably to the antagonists, including a salt, solvate or isomer (tautomer, desmotrop, and optically active isomer) thereof, to a pharmaceutical composition containing the ligand, to the use of the ligand, to its preparation, and intermediates of the ligand of the general formula (II″), (III″), (IV″), (V″), (VI″), (VII″), (VIII″) and (XIII″) and their preparation.
摘要翻译： 本发明涉及通式（I）的腺苷A3受体配体，其中优选包括其盐，溶剂化物或异构体（互变异构体，去质性和旋光异构体）的拮抗剂，包含其中的 （II“），（III”），（IV“），（V”），（VI“）的配体的中间体，配体的使用，配体的使用， ），（VII“），（VIII”）和（XIII“）及其制备。
-
公开(公告)号：US07709489B2
公开(公告)日：2010-05-04
申请号：US12140512
申请日：2008-06-17
申请人： Peter Aranyi , Laszlo Balazs , Maria Balogh , Sandor Batori , Lajos T. Nagy , Geza Timari , Kinga Boer , Zoltan Kapui , Endre Mikus , Katalin Gerber , Judit Vargane Szeredi , Katalin Urban-Szabo , Erzsebet Walcz
发明人： Peter Aranyi , Laszlo Balazs , Maria Balogh , Sandor Batori , Lajos T. Nagy , Geza Timari , Kinga Boer , Zoltan Kapui , Endre Mikus , Katalin Gerber , Judit Vargane Szeredi , Katalin Urban-Szabo , Erzsebet Walcz
IPC分类号： A61K31/496 , C07D403/14 , C07D403/06
CPC分类号： C07D471/04 , A61K31/415
摘要： This invention is directed to a compound of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, Z, m, n, o, p and r are as defined herein, its preparation, pharmaceutical composition and use as an adenosine A3 receptor ligand preferably an antagonist.
摘要翻译： 本发明涉及式（I）化合物，其中R 1，R 2，R 3，R 4，R 5，R 6，R 7，R 8，R 9，R 10，X，Z，m，n，o，p和r如 本文中，其制备，药物组合物和用作腺苷A3受体配体优选为拮抗剂。
-
公开(公告)号：US20050070566A1
公开(公告)日：2005-03-31
申请号：US10499251
申请日：2002-12-17
申请人： Peter Aranyl , Laszlo Balazs , Maria Balogh , Sandor Batori , Kinga Boer , Katalin Gerber , Zoltan Kapui , Endre Mikus , Geza Timari , T. Lajos , Katalin Urban-Szabo , Judit Vargane Szeredi
发明人： Peter Aranyl , Laszlo Balazs , Maria Balogh , Sandor Batori , Kinga Boer , Katalin Gerber , Zoltan Kapui , Endre Mikus , Geza Timari , T. Lajos , Katalin Urban-Szabo , Judit Vargane Szeredi
IPC分类号： C07D215/54 , A61K31/437 , A61K31/4545 , A61K31/4706 , A61K31/4709 , A61P1/04 , A61P3/04 , A61P3/10 , A61P7/00 , A61P9/00 , A61P9/06 , A61P9/08 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/12 , A61P17/00 , A61P17/04 , A61P17/06 , A61P19/02 , A61P25/00 , A61P25/16 , A61P25/24 , A61P25/28 , A61P27/02 , A61P27/06 , A61P27/16 , A61P29/00 , A61P35/00 , A61P37/02 , A61P37/08 , A61P43/00 , C07D215/56 , C07D405/12 , C07D409/12 , C07D471/04 , C07D487/04 , A61K31/4745 , C07D455/04
CPC分类号： C07D471/04
摘要： The present invention relates to adenosine A3 receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containings them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and (heir salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and (III) and to the preparation thereof.
摘要翻译： 本发明涉及通式（I）的腺苷A3受体配体，其中优选的是拮抗剂，以及它们的盐，溶剂化物和异构体，并且药物组合物包含它们，以使用通式（ I）以及它们的盐，溶剂合物和异构体制备通式（I）的化合物和（继续人的盐，溶剂合物和异构体，以及通式（II）和（III）的新中间体 ）及其制备。
-
公开(公告)号：US20050124648A1
公开(公告)日：2005-06-09
申请号：US10499250
申请日：2002-12-17
申请人： Peter Aranyi , Laszlo Balazs , Sandor Batori , Judit Bence , Kinga Boer , Felix Hadju , Zoltan Kapui , Endre Mikus , Tibor Szabo , Lajos T. Nagy , Geza Timari , Katalin Urban-Szabo , Erzsebet Walcz
发明人： Peter Aranyi , Laszlo Balazs , Sandor Batori , Judit Bence , Kinga Boer , Felix Hadju , Zoltan Kapui , Endre Mikus , Tibor Szabo , Lajos T. Nagy , Geza Timari , Katalin Urban-Szabo , Erzsebet Walcz
IPC分类号： A61K31/437 , A61K31/444 , A61P9/00 , A61P11/00 , A61P13/12 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/02 , A61P37/06 , C07B61/00 , C07D215/54 , C07D215/56 , C07D471/04 , A61K31/4745
CPC分类号： C07D471/04 , C07D215/54 , C07D215/56
摘要： The present invention relates to adenosine A-3? receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containing them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and theirs salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and to the preparation thereof.
摘要翻译： 本发明涉及腺苷A-
3？ 通式（I）的受体配体，在这些优选的拮抗剂中，以及它们的盐，溶剂合物和异构体，以及含有它们的药物组合物，通式（I）的化合物以及它们的 盐，溶剂合物和异构体，制备通式（I）化合物及其盐，溶剂合物和异构体，以及通式（II）的新中间体及其制备方法。
-
公开(公告)号：US07713992B2
公开(公告)日：2010-05-11
申请号：US12039272
申请日：2008-02-28
申请人： Peter Aranyi , Laszlo Balazs , Sandor Batori , Judit Bence , Kinga Boer , Felix Hajdu , Zoltan Kapui , Endre Mikus , Tibor Szabo , Lajos T. Nagy , Geza Timari , Katalin Urban-Szabo , Erzsebet Walcz
发明人： Peter Aranyi , Laszlo Balazs , Sandor Batori , Judit Bence , Kinga Boer , Felix Hajdu , Zoltan Kapui , Endre Mikus , Tibor Szabo , Lajos T. Nagy , Geza Timari , Katalin Urban-Szabo , Erzsebet Walcz
IPC分类号： A61K31/4355 , A61K31/4196
CPC分类号： C07D471/04 , C07D215/54 , C07D215/56
摘要： The present invention relates to adenosine A3 receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containing them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and their salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and to the preparation thereof.
摘要翻译： 本发明涉及通式（I）的腺苷A3受体配体，其中优选为拮抗剂，以及它们的盐，溶剂化物和异构体，以及含有它们的药物组合物，以及通式 I）以及它们的盐，溶剂合物和异构体，通式（I）的化合物及其盐，溶剂合物和异构体的制备，以及通式（II）的新中间体和制备 其中。
-
公开(公告)号：US07365089B2
公开(公告)日：2008-04-29
申请号：US10499250
申请日：2002-12-17
申请人： Peter Aranyi , Laszlo Balazs , Sandor Batori , Judit Bence , Kinga Boer , Felix Hajdu , Zoltan Kapui , Endre Mikus , Tibor Szabo , Lajos T. Nagy , Geza Timari , Katalin Urban-Szabo , Erzsebet Walcz
发明人： Peter Aranyi , Laszlo Balazs , Sandor Batori , Judit Bence , Kinga Boer , Felix Hajdu , Zoltan Kapui , Endre Mikus , Tibor Szabo , Lajos T. Nagy , Geza Timari , Katalin Urban-Szabo , Erzsebet Walcz
IPC分类号： A61K31/4196 , A61K31/4406 , C07D251/72
CPC分类号： C07D471/04 , C07D215/54 , C07D215/56
摘要： The present invention relates to adenosine A3? receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containing them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and theirs salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and to the preparation thereof.
摘要翻译： 本发明涉及腺苷A
3？ 通式（I）的受体配体，在这些优选的拮抗剂中，以及它们的盐，溶剂合物和异构体，以及含有它们的药物组合物，通式（I）的化合物以及它们的 盐，溶剂合物和异构体，制备通式（I）化合物及其盐，溶剂合物和异构体，以及通式（II）的新中间体及其制备方法。
-
公开(公告)号：US20080146604A1
公开(公告)日：2008-06-19
申请号：US12039272
申请日：2008-02-28
申请人： Peter Aranyi , Laszlo Balazs , Sandor Batori , Judit Bence , Kinga Boer , Felix Hajdu , Zoltan Kapui , Endre Mikus , Tibor Szabo , Lajos T. Nagy , Geza Timari , Katalin Urban-Szabo , Erzsebet Walcz
发明人： Peter Aranyi , Laszlo Balazs , Sandor Batori , Judit Bence , Kinga Boer , Felix Hajdu , Zoltan Kapui , Endre Mikus , Tibor Szabo , Lajos T. Nagy , Geza Timari , Katalin Urban-Szabo , Erzsebet Walcz
CPC分类号： C07D471/04 , C07D215/54 , C07D215/56
摘要： The present invention relates to adenosine A3 receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containing them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and their salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and to the preparation thereof.
摘要翻译： 本发明涉及通式（I）的腺苷A 3 N 3受体配体，其中优选的是拮抗剂，以及它们的盐，溶剂化物和异构体，以及含有它们的药物组合物 的通式（I）化合物及其盐，溶剂合物和异构体制备通式（I）化合物及其盐，溶剂合物和异构体，此外还涉及一般的新的中间体 式（II）及其制备方法。
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.041 秒)
